Cargando…

Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]

BACKGROUND: Persistent smoking among patients diagnosed with cancer is associated with adverse clinical outcomes, yet an evidence-based tobacco use intervention has not been well-integrated into cancer care in community oncology settings. This paper describes the protocol of a nation-wide clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Goshe, Brett M., Rasmussen, Autumn W., Wagner, Lynne I., Sicks, JoRean D., Gareen, Ilana F., Carlos, Ruth C., Herman, Benjamin A., Walter, Angela Wangari, Regan, Susan, Levy, Douglas E., Mahon, Irene, Muzikansky, Alona, Neil, Jordan M., Lui, Michelle, Dilip, Deepika, Malloy, Laura, Gonzalez, Irina, Finkelstein-Fox, Lucy, McCann, Caitlin, Perez, Elissa, Ostroff, Jamie S., Park, Elyse R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284951/
https://www.ncbi.nlm.nih.gov/pubmed/35841024
http://dx.doi.org/10.1186/s12889-022-13631-w
_version_ 1784747674887520256
author Goshe, Brett M.
Rasmussen, Autumn W.
Wagner, Lynne I.
Sicks, JoRean D.
Gareen, Ilana F.
Carlos, Ruth C.
Herman, Benjamin A.
Walter, Angela Wangari
Regan, Susan
Levy, Douglas E.
Mahon, Irene
Muzikansky, Alona
Neil, Jordan M.
Lui, Michelle
Dilip, Deepika
Malloy, Laura
Gonzalez, Irina
Finkelstein-Fox, Lucy
McCann, Caitlin
Perez, Elissa
Ostroff, Jamie S.
Park, Elyse R.
author_facet Goshe, Brett M.
Rasmussen, Autumn W.
Wagner, Lynne I.
Sicks, JoRean D.
Gareen, Ilana F.
Carlos, Ruth C.
Herman, Benjamin A.
Walter, Angela Wangari
Regan, Susan
Levy, Douglas E.
Mahon, Irene
Muzikansky, Alona
Neil, Jordan M.
Lui, Michelle
Dilip, Deepika
Malloy, Laura
Gonzalez, Irina
Finkelstein-Fox, Lucy
McCann, Caitlin
Perez, Elissa
Ostroff, Jamie S.
Park, Elyse R.
author_sort Goshe, Brett M.
collection PubMed
description BACKGROUND: Persistent smoking among patients diagnosed with cancer is associated with adverse clinical outcomes, yet an evidence-based tobacco use intervention has not been well-integrated into cancer care in community oncology settings. This paper describes the protocol of a nation-wide clinical trial conducted by the ECOG-ACRIN National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base to assess the effectiveness of a virtual tobacco treatment intervention and the process of implementing tobacco treatment in NCORP community oncology settings. METHODS/DESIGN: This two-arm, multisite (n: 49 NCORP sites) hybrid type 1 effectiveness-implementation randomized controlled trial compares the effectiveness of a Virtual Intervention Treatment (VIT) versus an Enhanced Usual Control (EUC) among English and Spanish speaking patients recently diagnosed with cancer, reporting current smoking and receiving care at a participating NCORP Community or Minority/Underserved Site. The VIT includes up to 11 virtual counseling sessions with a tobacco treatment specialist and up to 12 weeks of nicotine replacement therapy (NRT). The EUC arm receives a referral to the NCI Quitline. The primary study outcome is biochemically confirmed 7-day point prevalence smoking abstinence. Moderators of treatment effect will be assessed. The study evaluates implementation processes from participating NCORP site staff via survey, administrative, and focus group data, including reach, acceptability, appropriateness, fidelity, feasibility, adoption, cost and sustainability outcomes. DISCUSSION: This trial will generate findings about the effectiveness of an evidence-based virtual tobacco treatment intervention targeting patients diagnosed with cancer and illuminate barriers and facilitators that influence implementing tobacco treatment into community oncology settings nationally. In the era of COVID-19, virtual care solutions are vital for maximizing access and utilization of tobacco treatment delivery. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03808818) on January 18th, 2019; Last update posted: May 21st, 2020.
format Online
Article
Text
id pubmed-9284951
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92849512022-07-15 Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0] Goshe, Brett M. Rasmussen, Autumn W. Wagner, Lynne I. Sicks, JoRean D. Gareen, Ilana F. Carlos, Ruth C. Herman, Benjamin A. Walter, Angela Wangari Regan, Susan Levy, Douglas E. Mahon, Irene Muzikansky, Alona Neil, Jordan M. Lui, Michelle Dilip, Deepika Malloy, Laura Gonzalez, Irina Finkelstein-Fox, Lucy McCann, Caitlin Perez, Elissa Ostroff, Jamie S. Park, Elyse R. BMC Public Health Study Protocol BACKGROUND: Persistent smoking among patients diagnosed with cancer is associated with adverse clinical outcomes, yet an evidence-based tobacco use intervention has not been well-integrated into cancer care in community oncology settings. This paper describes the protocol of a nation-wide clinical trial conducted by the ECOG-ACRIN National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base to assess the effectiveness of a virtual tobacco treatment intervention and the process of implementing tobacco treatment in NCORP community oncology settings. METHODS/DESIGN: This two-arm, multisite (n: 49 NCORP sites) hybrid type 1 effectiveness-implementation randomized controlled trial compares the effectiveness of a Virtual Intervention Treatment (VIT) versus an Enhanced Usual Control (EUC) among English and Spanish speaking patients recently diagnosed with cancer, reporting current smoking and receiving care at a participating NCORP Community or Minority/Underserved Site. The VIT includes up to 11 virtual counseling sessions with a tobacco treatment specialist and up to 12 weeks of nicotine replacement therapy (NRT). The EUC arm receives a referral to the NCI Quitline. The primary study outcome is biochemically confirmed 7-day point prevalence smoking abstinence. Moderators of treatment effect will be assessed. The study evaluates implementation processes from participating NCORP site staff via survey, administrative, and focus group data, including reach, acceptability, appropriateness, fidelity, feasibility, adoption, cost and sustainability outcomes. DISCUSSION: This trial will generate findings about the effectiveness of an evidence-based virtual tobacco treatment intervention targeting patients diagnosed with cancer and illuminate barriers and facilitators that influence implementing tobacco treatment into community oncology settings nationally. In the era of COVID-19, virtual care solutions are vital for maximizing access and utilization of tobacco treatment delivery. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03808818) on January 18th, 2019; Last update posted: May 21st, 2020. BioMed Central 2022-07-15 /pmc/articles/PMC9284951/ /pubmed/35841024 http://dx.doi.org/10.1186/s12889-022-13631-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Goshe, Brett M.
Rasmussen, Autumn W.
Wagner, Lynne I.
Sicks, JoRean D.
Gareen, Ilana F.
Carlos, Ruth C.
Herman, Benjamin A.
Walter, Angela Wangari
Regan, Susan
Levy, Douglas E.
Mahon, Irene
Muzikansky, Alona
Neil, Jordan M.
Lui, Michelle
Dilip, Deepika
Malloy, Laura
Gonzalez, Irina
Finkelstein-Fox, Lucy
McCann, Caitlin
Perez, Elissa
Ostroff, Jamie S.
Park, Elyse R.
Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
title Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
title_full Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
title_fullStr Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
title_full_unstemmed Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
title_short Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]
title_sort study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [smokefree support study 2.0]
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284951/
https://www.ncbi.nlm.nih.gov/pubmed/35841024
http://dx.doi.org/10.1186/s12889-022-13631-w
work_keys_str_mv AT goshebrettm studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT rasmussenautumnw studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT wagnerlynnei studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT sicksjoreand studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT gareenilanaf studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT carlosruthc studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT hermanbenjamina studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT walterangelawangari studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT regansusan studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT levydouglase studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT mahonirene studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT muzikanskyalona studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT neiljordanm studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT luimichelle studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT dilipdeepika studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT malloylaura studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT gonzalezirina studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT finkelsteinfoxlucy studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT mccanncaitlin studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT perezelissa studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT ostroffjamies studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20
AT parkelyser studyprotocolforahybridtype1effectivenessimplementationtrialtestingvirtualtobaccotreatmentinoncologypracticessmokefreesupportstudy20